Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Accumulating evidence implicates the tumor-draining lymph node (TDLN) in tumor-induced immune escape, as it drains regulatory molecules and leukocytes from the tumor microenvironment. We asked whether targeted delivery of adjuvant to the TDLN, presumably already bathed in tumor antigens, could promote anti-tumor immunity and hinder tumor growth. To this end, we used 30 nm polymeric nanoparticles (NPs) that effectively target dendritic cells (DCs, CD11c(+)) within the lymph node (LN) after intradermal administration. These NPs accumulated within the TDLN when administered in the limb ipsilateral (i.l.) to the tumor or in the non-TDLN when administered in the contralateral (c.l.) limb. Incorporating the adjuvants CpG or paclitaxel into the NPs (CpG-NP and PXL-NP) induced DC maturation in vitro. When administered daily i.l. and thus targeting the TDLN of a B16-F10 melanoma, adjuvanted NPs induced DC maturation within the TDLN and reshaped the CD4(+) T cell distribution within the tumor towards a Th1 (CXCR3(+)) phenotype. Importantly, this also led to an increase in the frequency of antigen-specific CD8(+) T cells within the tumor. This correlated with slowed tumor growth, in contrast to unhindered tumor growth after c.l. delivery of adjuvanted NPs (targeting a non-TDLN) or i.l. delivery of free adjuvant. CpG-NP treatment in the i.l. limb also was associated with an increase in CD8(+)/CD4(+) T cell ratios and frequencies of activated (CD25(+)) CD8(+) T cells within the TDLN whereas PXL-NP treatment reduced the frequency of regulatory T (FoxP3(+) CD4(+)) cells in the TDLN. Together, these data implicate the TDLN as a delivery target for adjuvant therapy of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 1×
“Cancer immunotherapy aims to activate or enhance the patient’s adaptive immune system to kill tumor cells with antigen specificity [1].”
BackgroundKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Lymphangiogenesis: Molecular Mechanisms and Future Promise
Tammela, T., & Alitalo, K. (2010) · Cell · doi:10.1016/j.cell.2010.01.045 · Cited by 1,441
CCR7 and its ligands: balancing immunity and tolerance
Förster, R., Davalos-Misslitz, A. C., & Rot, A. (2008) · Nature Reviews Immunology · doi:10.1038/nri2297 · Cited by 1,410
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O'Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,350
Self-citationSeong, S.-Y., & Matzinger, P. (2004) · Nature Reviews Immunology · doi:10.1038/nri1372 · Cited by 1,220
Dendritic-cell trafficking to lymph nodes through lymphatic vessels
Randolph, G. J., Angeli, V., & Swartz, M. A. (2005) · Nature Reviews Immunology · doi:10.1038/nri1670 · Cited by 1,111
Self-citationImmunotherapeutic uses of CpG oligodeoxynucleotides
Klinman, D. M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1329 · Cited by 1,012
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845
In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles
Reddy, S. T., Rehor, A., Schmoekel, H. G., Hubbell, J. A., & Swartz, M. A. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.006 · Cited by 679
Self-citationMaterials engineering for immunomodulation
Hubbell, J. A., Thomas, S. N., & Swartz, M. A. (2009) · Nature · doi:10.1038/nature08604 · Cited by 561
Self-citationRomero, P., Rod Dunbar, P., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J.-L., Liénard, D., Cerottini, J.-C., & Cerundolo, V. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1641 · Cited by 521
Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J. M., & Swartz, M. A. (2010) · Science · doi:10.1126/science.1185837 · Cited by 506
Self-citationImmunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Piersma, S. J., Jordanova, E. S., van Poelgeest, M. I. E., Kwappenberg, K. M. C., van der Hulst, J. M., Drijfhout, J. W., Melief, C. J. M., Kenter, G. G., Fleuren, G. J., Offringa, R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3388 · Cited by 414 · cited 1×
“3GeI), as did CD8þ:CD4þ T cell ratio, which has been shown to correlate with decreased lymph node metastasis in human papillomavirusinduced cervical cancer [49] and survival in metastatic melanoma patients receiving chemotherapy [50].”
BackgroundPerera, P.-Y., Mayadas, T. N., Takeuchi, O., Akira, S., Zaks-Zilberman, M., Goyert, S. M., & Vogel, S. N. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.574 · Cited by 391
Kawasaki, K., Akashi, S., Shimazu, R., Yoshida, T., Miyake, K., & Nishijima, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2251 · Cited by 355
Lund, A. W., Duraes, F. V., Hirosue, S., Raghavan, V. R., Nembrini, C., Thomas, S. N., Issa, A., Hugues, S., & Swartz, M. A. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.01.005 · Cited by 341
Self-citationDendritic cell dysfunction in cancer: A mechanism for immunosuppression
Pinzon‐Charry, A., Maxwell, T., & López, J. A. (2005) · Immunology & Cell Biology · doi:10.1111/j.1440-1711.2005.01371.x · Cited by 328
CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells
Schneider, M. A., Meingassner, J. G., Lipp, M., Moore, H. D., & Rot, A. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061405 · Cited by 321
The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol
Byrd-Leifer, C. A., Block, E. F., Takeda, K., Akira, S., & Ding, A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200108)31:8<2448::aid-immu2448>3.0.co;2-n · Cited by 287
Therapeutic Cancer Vaccines: Current Status and Moving Forward
Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282
Jewell, C. M., Bustamante López, S. C., & Irvine, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105200108 · Cited by 245
Hirosue, S., Kourtis, I. C., van der Vlies, A. J., Hubbell, J. A., & Swartz, M. A. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.09.077 · Cited by 233
Self-citationGarnett, C. T., Schlom, J., & Hodge, J. W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4025 · Cited by 232
Engineering Approaches to Immunotherapy
Swartz, M. A., Hirosue, S., & Hubbell, J. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003763 · Cited by 224
Self-citationPashenkov, M., Goëss, G., Wagner, C., Hörmann, M., Jandl, T., Moser, A., Britten, C. M., Smolle, J., Koller, S., Mauch, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9129 · Cited by 210
Heckelsmiller, K., Rall, K., Beck, S., Schlamp, A., Seiderer, J., Jahrsdörfer, B., Krug, A., Rothenfusser, S., Endres, S., & Hartmann, G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3892 · Cited by 194
Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination
Nembrini, C., Stano, A., Dane, K. Y., Ballester, M., van der Vlies, A. J., Marsland, B. J., Swartz, M. A., & Hubbell, J. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104264108 · Cited by 187
Self-citationOchando, J. C., Yopp, A. C., Yang, Y., Garin, A., Li, Y., Boros, P., Llodra, J., Ding, Y., Lira, S. A., Krieger, N. R., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6993 · Cited by 182
Cochran, A. J., Morton, D. L., Stern, S., Lana, A. M. A., Essner, R., & Wen, D.-R. (2001) · Modern Pathology · doi:10.1038/modpathol.3880358 · Cited by 165
Maruyama, T., Kono, K., Mizukami, Y., Kawaguchi, Y., Mimura, K., Watanabe, M., Izawa, S., & Fujii, H. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01624.x · Cited by 163
Oxidation-Sensitive Polymeric Nanoparticles
Rehor, A., Hubbell, J. A., & Tirelli, N. (2005) · Langmuir · doi:10.1021/la0478043 · Cited by 161
Self-citationMenning, A., Höpken, U. E., Siegmund, K., Lipp, M., Hamann, A., & Huehn, J. (2007) · European Journal of Immunology · doi:10.1002/eji.200737201 · Cited by 160
Deng, L., Zhang, H., Luan, Y., Zhang, J., Xing, Q. R., Dong, S., Wu, X., Liu, M., & Wang, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1073 · Cited by 155
Kourtis, I. C., Hirosue, S., de Titta, A., Kontos, S., Stegmann, T., Hubbell, J. A., & Swartz, M. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061646 · Cited by 145
Self-citationEngineering complement activation on polypropylene sulfide vaccine nanoparticles
Thomas, S. N., van der Vlies, A. J., O’Neil, C. P., Reddy, S. T., Yu, S. S., Giorgio, T. D., Swartz, M. A., & Hubbell, J. A. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.037 · Cited by 135
Self-citationMolenkamp, B. G., Sluijter, B. J. R., van Leeuwen, P. A. M., Santegoets, S. J. A. M., Meijer, S., Wijnands, P. G. J. T. B., Haanen, J. B. A. G., van den Eertwegh, A. J. M., Scheper, R. J., & de Gruijl, T. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4711 · Cited by 135
Weigel, B. J., Rodeberg, D. A., Krieg, A. Μ., & Blazar, B. R. (2003) · PubMed · Cited by 133
Molenkamp, B. G., van Leeuwen, P. A. M., Meijer, S., Sluijter, B. J. R., Wijnands, P. G. J. T. B., Baars, A., van den Eertwegh, A. J. M., Scheper, R. J., & de Gruijl, T. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0050 · Cited by 131
Ballester, M., Nembrini, C., Dhar, N., de Titta, A., de Piano, C., Pasquier, M., Simeoni, E., van der Vlies, A. J., McKinney, J. D., Hubbell, J. A., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.039 · Cited by 130 · cited 3×
“Here, to chemically conjugate CpG to the NP surface, we utilized pyridyl disulfidefunctionalized NPs, the synthesis [40] and use of which in conjugating thiol-containing protein antigens [23,24,41] have been previously reported.”
BackgroundMethodSelf-citationvan der Vlies, A. J., O’Neil, C. P., Hasegawa, U., Hammond, N. A., & Hubbell, J. A. (2010) · Bioconjugate Chemistry · doi:10.1021/bc9004443 · Cited by 111
Self-citationDane, K. Y., Nembrini, C., Tomei, A. A., Eby, J. K., O’Neil, C. P., Velluto, D., Swartz, M. A., Inverardi, L., & Hubbell, J. A. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.009 · Cited by 109
Self-citationNierkens, S., den Brok, M. H., Roelofsen, T., Wagenaars, J. A. L., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008368 · Cited by 108
Wu, A., Oh, S., Gharagozlou, S., Vedi, R. N., Ericson, K., Low, W. C., Chen, W., & Ohlfest, J. R. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318155a0f6 · Cited by 75
Azuma, M., Ebihara, T., Oshiumi, H., Matsumoto, M., & Seya, T. (2012) · OncoImmunology · doi:10.4161/onci.19893 · Cited by 75
Stano, A., van der Vlies, A. J., Martino, M. M., Swartz, M. A., Hubbell, J. A., & Simeoni, E. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.11.010 · Cited by 73
Self-citationMattarollo, S. R., Steegh, K., Li, M., Duret, H., Ngiow, S. F., & Smyth, M. J. (2012) · Immunology and Cell Biology · doi:10.1038/icb.2012.58 · Cited by 46
Nanoparticle Migration and Delivery of Paclitaxel to Regional Lymph Nodes in a Large Animal Model
Khullar, O. V., Griset, A. P., Gibbs‐Strauss, S. L., Chirieac, L. R., Zubris, K. A. V., Frangioni, J. V., Grinstaff, M. W., & Colson, Y. L. (2012) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2011.11.006 · Cited by 45
Extralymphatic Tumors Prepare Draining Lymph Nodes to Invasion via a T-Cell Cross-Tolerance Process
Preynat-Seauve, O., Contassot, E., Schuler, P., Piguet, V., French, L. E., & Huard, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4494 · Cited by 45
Fujita, T., Teramoto, K., Ozaki, Y., Hanaoka, J., Tezuka, N., Itoh, Y., Asai, T., Fujino, S., Kontani, K., & Ogasawara, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2499 · Cited by 35
Outlining novel cellular adjuvant products for therapeutic vaccines against cancer
Nitcheu-Tefit, J., & Serra, V. A. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.84 · Cited by 34
High Immunogenicity of the Human Leukocyte Antigen Peptidomes of Melanoma Tumor Cells
Jarmalavicius, S., Welte, Y., & Walden, P. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.358903 · Cited by 33
Yang, L., Sun, L., Wu, X., Wang, L., Wei, H., Wan, M., Zhang, P., Yu, Y., & Wang, L. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.01.011 · Cited by 20
(2001) · PubMed
Cited by
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
From Sewer to Saviour—Targeting the Lymphatic System to Promote Drug Exposure and Activity
Trevaskis, N. L., Kaminskas, L. M., & Porter, C. J. H. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4608 · Cited by 654
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Nanoparticle-Based Immunotherapy for Cancer
Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., & Santamaria, P. (2015) · ACS Nano · doi:10.1021/nn5062029 · Cited by 470
Metadata
- Authors
- Thomas, S. N., Vokali, E., Lund, A. W., Hubbell, J. A., & Swartz, M. A.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 35
- Issue
- 2
- Pages
- 814-824
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W1987416012
- Cited by
- 310
- References
- 55
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.